-- Ace Therapeutics, a specialized contract research organization (CRO) focused on respiratory and infectious disease preclinical research, unveiled its full-spectrum respiratory infection model development service platform, designed to address unmet translational gaps for researchers advancing novel therapeutics against bacterial, viral, mycobacterial and fungal pulmonary pathogens. The platform centers on tailored study design featuring custom preclinical respiratory infection models, alongside integrated PK/PD analysis capabilities to link drug exposure directly to in vivo therapeutic efficacy.
Respiratory infectious diseases remain a persistent global public health burden, with emerging resistant pathogens and complex polymicrobial conditions slowing the translation of early-stage drug candidates into clinical assets. Ace Therapeutics’ new service portfolio resolves this challenge by combining bespoke model engineering with unified multi-parametric endpoint testing for streamlined, data-rich preclinical pipelines.
Ace Therapeutics’ custom preclinical respiratory infection models are built to align with clients’ research objectives. Its scientific team customizes every layer of the infection study framework, including pathogen selection (reference strains, clinical isolates, drug-resistant variants, and genetically modified microbes), host animal backgrounds (immunocompetent, neutropenic, genetically edited knockout and humanized rodents, plus alternative species such as cotton rats and tree shrews), infection routes (intranasal, intratracheal, aerosol, oropharyngeal aspiration), and disease progression profiles spanning acute lethal, self-resolving subacute, chronic persistent, and pathogen reactivation phenotypes. Supported model categories cover bacterial pneumonia, viral respiratory illness, mycobacterial tuberculosis-like infection, fungal pulmonary disease, and polymicrobial biofilm-driven chronic lung infection, with standardized and customizable tissue sampling, survival monitoring, and longitudinal burden quantification workflows.
To maximize the value of each infection model, Ace Therapeutics offers a comprehensive suite of downstream analyses that can be integrated into clients’ study design, such as microbiological evaluation, immunological profiling, and PK/PD analysis in infection models. Rather than separating pharmacokinetic sampling and efficacy testing across discrete animal trials, Ace Therapeutics conducts coordinated tissue and plasma drug concentration measurements alongside core infection readouts within a single animal cohort. This integrated approach generates direct exposure-response datasets by correlating lung and epithelial lining fluid drug levels with key efficacy endpoints, including microbial CFU or viral titer reduction, survival benefit, lung tissue injury scores and inflammatory cytokine signatures.
Ace Therapeutics incorporates rigorous quality control measures across inoculum preparation, animal housing, infection procedures and tissue collection, with matched control groups embedded within every trial to eliminate confounding variables. Post-study deliverables include complete raw datasets, statistical evaluations, high-resolution histology imagery, and consolidated executive reports formatted for internal program review and regulatory submission requirements, with full data ownership and client confidentiality guaranteed.
Clients seeking to launch respiratory infectious disease preclinical work can schedule free pre-study consultation sessions with Ace Therapeutics to refine model design, pathogen selection, infection route planning, and endpoint panels before initiating formal in vivo trials.
About Ace Therapeutics
Ace Therapeutics is a specialized contract research organization delivering tailored preclinical modeling and research services focused on respiratory and infectious disease research. Staffed by veteran respiratory and infection biology scientists, Ace Therapeutics designs reproducible, translational animal models, and integrated analytical workflows to support every stage of antimicrobial, antiviral, antifungal, and immunomodulatory drug development. Its service suite prioritizes custom study design, integrated PK/PD profiling and robust regulatory-grade data generation to accelerate the translation of novel therapeutics addressing global respiratory health threats.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/
Release ID: 89200770
Google
RSS